AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Chronic Kidney Disease | Dapagliflozin | Forxiga | India Health | Pharmaceuticals | Urology & Nephrology